VCYT · Veracyte, Inc.
$55.70
+0.05 (+0.08%)
At close · Jul 29
Market Cap
$4.44B
Shares
79.79M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$517.15M
+16%
FY2025
Net Income
$66.35M
+174.9%
FY2025
Gross Margin
70.1%
+3.2pp
FY2025
Operating Margin
11.17%
+7.6pp
FY2025
Diluted EPS
$0.82
+164.5%
FY2025
Operating Cash Flow
$136.31M
+81.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $541.74M | $517.15M | $445.76M | $361.05M | $296.54M | $219.51M | $117.48M | $120.37M | $92.01M | $71.95M | $65.09M | $49.5M | $38.19M | $21.88M | $11.63M | $2.65M | |
| — | — | — | — | — | — | — | $36.08M | $33.08M | $28.2M | $25.46M | $21.5M | $16.61M | $12.61M | $7.58M | $2.93M | |
| $384.18M | $362.53M | $298.15M | $229.68M | $175.68M | — | — | — | — | — | — | — | — | — | — | — | |
| — | 70.1% | 66.88% | 63.62% | 59.24% | — | — | — | — | — | — | — | — | — | — | — | |
| $80.19M | $70.81M | $69.29M | $57.31M | $40.6M | $29.84M | $17.2M | $14.85M | $14.82M | $13.88M | $15.32M | $12.8M | $9.8M | $7.81M | $6.61M | $6.68M | |
| $102.87M | $100.17M | $95.43M | $101.49M | $97.56M | $79.84M | $52.39M | $53.69M | $41.31M | $32.26M | $28.25M | $25.29M | $21.93M | $12.54M | $8.45M | $2.93M | |
| $100.66M | $110.78M | $110.61M | $86.23M | $73.2M | $101.35M | $36.73M | $29.03M | $23.96M | $23.09M | $23.79M | $22.58M | $18.85M | $12.1M | $7.92M | $5.37M | |
| $13.3M | $13.2M | $14.8M | $20.6M | $21.4M | $15.98M | $5.1M | $1.4M | $1.07M | $1.1M | $1.1M | $800K | $0 | — | — | — | |
| — | $21.42M | $23.46M | $27.19M | $25.93M | $19.59M | $7.94M | $4.12M | $3.92M | $3.84M | $3.51M | $2.25M | $1.18M | $999K | $706K | $611K | |
| — | — | — | — | — | — | — | — | $114.24M | $98.49M | $93.89M | $82.97M | $67.2M | $45.06M | $30.56M | $17.91M | |
| $306.66M | $304.76M | $282M | $315.48M | $216.76M | $301.42M | $152.87M | $135.5M | $114.24M | $98.49M | — | — | — | — | — | — | |
| $77.52M | $57.78M | $16.14M | -$85.8M | -$41.08M | -$81.9M | -$35.39M | -$15.13M | -$22.23M | -$26.54M | -$28.8M | -$33.47M | -$29.01M | -$23.17M | -$18.93M | -$15.27M | |
| — | 11.17% | 3.62% | -23.76% | -13.85% | -37.31% | -30.12% | -12.57% | -24.16% | -36.88% | -44.25% | -67.6% | -75.95% | -105.89% | -162.79% | -577.16% | |
| — | $79.19M | $39.6M | -$58.61M | -$15.15M | -$62.31M | -$27.45M | -$11.01M | -$18.31M | -$22.7M | -$25.29M | -$31.21M | -$27.83M | -$22.17M | -$18.22M | -$14.66M | |
| $225K | — | — | — | — | — | $229K | $677K | $1.96M | $4.94M | $2.76M | $378K | $439K | $233K | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | $5000 | $2000 | $2000 | |
| $13.23M | $10.42M | $9.6M | $9.18M | $4.65M | $254K | $480K | $2.53M | $1.2M | $476K | $202K | $140K | $72K | -$2.17M | $280K | $819K | |
| $90.75M | $68.2M | $25.74M | -$76.61M | -$36.43M | -$81.65M | -$34.91M | -$12.6M | -$23M | -$31M | -$31.4M | -$33.7M | -$29.4M | -$25.58M | -$18.6M | -$14.4M | |
| $2.73M | $1.85M | $1.61M | -$2.21M | $133K | -$6.09M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | |
| $88.01M | $66.35M | $24.14M | -$74.4M | -$36.56M | -$75.56M | -$34.91M | -$12.6M | -$23M | — | — | — | — | — | — | — | |
| — | 12.83% | 5.41% | -20.61% | -12.33% | -34.42% | -29.71% | -10.47% | -25% | — | — | — | — | — | — | — | |
| $88.01M | $66.35M | $24.14M | -$74.4M | -$36.56M | — | — | -$12.6M | -$23M | -$31M | -$31.36M | -$33.7M | -$29.37M | -$25.58M | -$18.65M | -$14.45M | |
| $108.43M | $94.23M | $12.07M | -$67.08M | -$52.82M | -$90.65M | -$34.91M | -$12.6M | -$23M | -$31M | -$31.36M | -$33.7M | -$29.37M | -$25.58M | -$18.65M | — | |
| USD/shares | — | $0.84 | $0.32 | -$1.02 | -$0.51 | -$1.11 | -$0.66 | -$0.27 | — | — | — | — | — | — | — | — |
| USD/shares | — | $0.82 | $0.31 | -$1.02 | -$0.51 | -$1.11 | -$0.66 | -$0.27 | — | — | — | — | — | — | — | — |
| shares | — | 78.58M | 76.48M | 72.64M | 71.55M | 67.89M | 53.24M | 46.14M | 37.02M | 33.93M | 28.83M | 25.99M | 21.64M | 4.16M | 650.33K | 580.06K |
| shares | — | 80.57M | 78.16M | 72.64M | 71.55M | 67.89M | 53.24M | 46.14M | 37.02M | 33.93M | 28.83M | 25.99M | 21.64M | 4.16M | 650.33K | 580.06K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.98×
EV/EBIT
—
Peer median 24.67×
P/E (TTM)
51.53×
Peer median 33.51×
Peer medians compare against the 27 similar-size Diagnostics & Research companies (of 48 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $517,145,000 | $445,764,000 | $361,051,000 | $296,536,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $496,598,000 | $423,537,000 | $334,525,000 | $262,923,000 | $200,982,000 | $109,614,000 | $119,153,000 | $91,773,000 |
| Non Us | $20,547,000 | $22,227,000 | $26,526,000 | $33,613,000 | $18,532,000 | $7,869,000 | $1,215,000 | $235,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Testing | $493,154,000 | $418,961,000 | $326,542,000 | $250,544,000 | $188,182,000 | $101,970,000 | $107,355,000 | $91,058,000 |
| Product | $14,327,000 | $13,650,000 | $15,588,000 | $12,632,000 | $11,464,000 | $9,845,000 | $923,000 | $0 |
| Biopharmaceutical and Other | $9,664,000 | $13,153,000 | $18,921,000 | $33,360,000 | $19,868,000 | $5,668,000 | $12,090,000 | — |
| Biopharmaceutical and Other Biopharmaceutical Revenue | $6,536,000 | $7,149,000 | $13,874,000 | $26,341,000 | $12,613,000 | $5,668,000 | — | — |
| Testing Other | $6,200,000 | $11,800,000 | $7,800,000 | $3,100,000 | $1,100,000 | — | — | — |
| Biopharmaceutical And Other Contract Manufacturing And Testing | $3,128,000 | $6,004,000 | $5,047,000 | $7,019,000 | $3,255,000 | $0 | — | — |
| Biopharmaceutical and Other Collaboration Milestones | — | — | $0 | $0 | $4,000,000 | $0 | $4,000,000 | — |
| Biopharmaceutical and Other Contract Manufacturing | — | — | — | — | $2,872,000 | $0 | $0 | — |
| Biopharmaceutical and Other Contract Testing | — | — | — | — | $383,000 | $0 | $0 | — |
| Biopharmaceutical and Other Development Rights | — | — | — | — | $0 | $1,000,000 | $0 | — |
| Biopharmaceutical and Other Development Services | — | — | — | — | $10,387,000 | $2,123,000 | $1,000,000 | — |
| Biopharmaceutical And Other Milestones Excluding Collaboration | — | — | — | — | $350,000 | $1,000,000 | $0 | — |
| Biopharmaceutical and Other Provision of Data | — | — | — | — | $1,876,000 | $1,545,000 | $7,090,000 | — |
| Biopharmaceutical | — | — | — | — | — | $5,668,000 | $8,090,000 | $950,000 |
| Collaboration | — | — | — | — | — | $0 | $4,000,000 | $0 |
Key facts
CIK
1384101
CUSIP
92337F107
13F (30d)
67 filings
67 filers
Visit website
Investor relations